Literature DB >> 8677878

Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem.

D Darbar1, M Smith, K Mörike, D M Roden.   

Abstract

Although increases in serum epinephrine are known to cause hypokalemia, the epinephrine dosages and concentrations at which this effect occurs, and the electrocardiographic consequences, have not been evaluated. Because epinephrine infusion is now being used to provoke arrhythmias in some patients, we have determined the physiologic effects of a range of dosages of epinephrine. The effects of pretreatment with propranolol and diltiazem on these indexes of epinephrine effect were also evaluated. Epinephrine dose ranging started at 10 ng/kg/min, with doubling of the dose every 10 minutes until a predetermined end point was reached. At the end of each dosage level, serum electrolytes, catecholamines, and an electrocardiogram were recorded. Whereas even the lowest dosage of epinephrine significantly increased heart rate, serum glucose levels increased and serum potassium decreased only when dosages of 160 to 320 ng/kg/min were administered. Plasma concentrations of epinephrine at these dosages were mean +/- SD 1,328 +/- 902 pg/ml, comparable to those observed in these subjects during maximal exercise (1,003 +/- 527 pg/ml). The major electrocardiographic effect of epinephrine infusion was a dose-related increase in QTc, but pretreatment with propranolol blunted this effect and tended to shorten QTc. At an epinephrine dose of 40 ng/kg/min, QTc prolongation persisted and was inhibited by diltiazem. These data suggest that the major electrocardiographic effect of epinephrine infusion is mediated by increased calcium current. At dosages > 80 ng/kg/min, plasma epinephrine concentrations are comparable to those observed with severe stress, and hypokalemia is common. The use of epinephrine as an electrophysiologic provoker at dosages > 80 ng/kg/min results in both a direct effect, as well as an indirect effect due to hypokalemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8677878     DOI: 10.1016/s0002-9149(96)00204-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Neurocardiology: therapeutic implications for cardiovascular disease.

Authors:  David S Goldstein
Journal:  Cardiovasc Ther       Date:  2010-11-25       Impact factor: 3.023

2.  Epinephrine bolus test in detecting long QT syndrome mutation carriers with indeterminable electrocardiographic phenotype.

Authors:  Anna-Mari Hekkala; Heikki Swan; Matti Viitasalo; Heikki Väänänen; Lauri Toivonen
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-04       Impact factor: 1.468

Review 3.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  The effect of patient-controlled intravenous analgesia on postoperative hypokalemia in patients undergoing laparoscopic cholecystectomy.

Authors:  Won Ho Kim; Jong Hwan Lee; Justin Sangwook Ko; Tae Soo Hahm; Sangmin M Lee; Hyun Sung Cho
Journal:  J Anesth       Date:  2011-08-24       Impact factor: 2.078

Review 5.  The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence.

Authors:  C Nordin
Journal:  Diabetologia       Date:  2010-04-21       Impact factor: 10.122

6.  Comparison of TWA and PEP as indices of α2- and ß-adrenergic activation.

Authors:  L Drost; J B Finke; J Port; H Schächinger
Journal:  Psychopharmacology (Berl)       Date:  2022-04-08       Impact factor: 4.530

Review 7.  The extended autonomic system, dyshomeostasis, and COVID-19.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2020-07-22       Impact factor: 4.435

8.  Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage.

Authors:  Shinji Fukui; Hiroshi Katoh; Nobusuke Tsuzuki; Shoichiro Ishihara; Naoki Otani; Hidetoshi Ooigawa; Terushige Toyooka; Akira Ohnuki; Takahito Miyazawa; Hiroshi Nawashiro; Katsuji Shima
Journal:  Crit Care       Date:  2003-02-21       Impact factor: 9.097

9.  Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects.

Authors:  Tulay Akman; Oytun Erbas; Levent Akman; Ahmet U Yilmaz
Journal:  Arq Bras Cardiol       Date:  2014-09-12       Impact factor: 2.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.